Artivion, Inc. (NYSE:AORT – Get Free Report) has been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $32.00.
A number of equities analysts recently commented on the stock. Canaccord Genuity Group assumed coverage on shares of Artivion in a research report on Tuesday, June 17th. They set a “buy” rating and a $35.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price target on shares of Artivion in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of Artivion in a research report on Tuesday, May 6th. Finally, Citizens Jmp raised shares of Artivion to a “strong-buy” rating in a research report on Tuesday, May 6th.
View Our Latest Stock Analysis on AORT
Artivion Stock Performance
Artivion (NYSE:AORT – Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.06). The company had revenue of $98.98 million for the quarter, compared to analyst estimates of $94.81 million. Artivion had a positive return on equity of 3.63% and a negative net margin of 5.49%. As a group, equities analysts predict that Artivion will post 0.37 EPS for the current year.
Insider Activity
In related news, SVP Marshall S. Stanton sold 10,548 shares of Artivion stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $29.13, for a total transaction of $307,263.24. Following the sale, the senior vice president now directly owns 105,332 shares in the company, valued at $3,068,321.16. This trade represents a 9.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jean F. Holloway sold 9,926 shares of Artivion stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $29.00, for a total transaction of $287,854.00. Following the sale, the senior vice president now owns 187,258 shares in the company, valued at approximately $5,430,482. This represents a 5.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 72,954 shares of company stock worth $2,108,525. Corporate insiders own 7.60% of the company’s stock.
Institutional Investors Weigh In On Artivion
Several hedge funds have recently added to or reduced their stakes in AORT. Legacy Advisors LLC acquired a new stake in Artivion during the 1st quarter worth approximately $28,000. MCF Advisors LLC lifted its position in shares of Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after purchasing an additional 614 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Artivion in the 4th quarter worth approximately $64,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Artivion in the 4th quarter worth approximately $194,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.
About Artivion
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Further Reading
- Five stocks we like better than Artivion
- What Are Growth Stocks and Investing in Them
- Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making?
- What Does a Stock Split Mean?
- Value Alert: 3 High-Yield Stocks Trading at 52-Week Lows
- What is a Microcap Stock? Everything You Need to Know
- Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.